Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:ATCCode |
L01EM03
|
| gptkbp:CASNumber |
915019-65-7
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:hasClinicalPhase |
Phase 2
|
| gptkbp:hasInChIKey |
QXJYVQXGBQGFGY-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H19N3O3
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=CC=CC=C12)C3=NC4=CC=CC=C4N3CCOCCO
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
CHEMBL1200713
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:isInChEMBLDatabase |
true
|
| gptkbp:IUPACName |
5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
|
| gptkbp:mechanismOfAction |
PI3K/mTOR dual inhibitor
|
| gptkbp:molecularWeight |
313.35
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1200713
11977753 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
Dactolisib
NVP-BEZ235 |
| gptkbp:target |
gptkb:PI3K
gptkb:mTOR |
| gptkbp:therapeuticArea |
oncology
|
| gptkbp:bfsParent |
gptkb:procaine
|
| gptkbp:bfsLayer |
7
|